Published in Cancer Discov on September 15, 2014
The Molecular Taxonomy of Primary Prostate Cancer. Cell (2015) 3.29
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep (2014) 1.09
Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet (2015) 1.08
Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1. Cell Rep (2015) 1.05
Pediatric solid tumor genomics and developmental pliancy. Oncogene (2015) 1.00
Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. J Exp Med (2015) 0.95
MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clin Cancer Res (2016) 0.86
The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget (2016) 0.85
Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget (2015) 0.85
Orthotopic patient-derived xenografts of paediatric solid tumours. Nature (2017) 0.83
The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Dev Biol (2015) 0.82
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes. Int J Mol Sci (2015) 0.82
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget (2016) 0.81
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget (2016) 0.81
Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev (2015) 0.81
Cohesin mutations in human cancer. Biochim Biophys Acta (2016) 0.81
Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience (2015) 0.80
Cancer genomics: why rare is valuable. J Mol Med (Berl) (2015) 0.80
Development and characterization of a human orthotopic neuroblastoma xenograft. Dev Biol (2015) 0.80
Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2. PLoS Genet (2016) 0.80
CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling. Oncogene (2015) 0.78
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget (2016) 0.78
ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev (2017) 0.77
Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity. Oncoimmunology (2016) 0.77
Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene (2015) 0.77
CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget (2016) 0.77
Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer (2016) 0.77
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. Genes Cancer (2015) 0.76
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med (2016) 0.76
An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development. Stem Cell Reports (2016) 0.76
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int (2016) 0.76
Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation. Mol Cancer Res (2015) 0.76
Management of Ewing sarcoma family of tumors: Current scenario and unmet need. World J Orthop (2016) 0.76
The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Genes Cancer (2015) 0.76
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein. Oncotarget (2016) 0.76
Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine. Trends Mol Med (2016) 0.76
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer (2017) 0.75
Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation. Cell Death Dis (2016) 0.75
Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations. Data Brief (2016) 0.75
Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications. Surg Pathol Clin (2015) 0.75
Recent advances in targeted therapy for Ewing sarcoma. F1000Res (2016) 0.75
Cooperation between somatic mutations and germline susceptibility variants in tumorigenesis - a dangerous liaison. Mol Cell Oncol (2015) 0.75
CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression. Oncotarget (2016) 0.75
C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Oncotarget (2017) 0.75
Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. J Pediatr Hematol Oncol (2016) 0.75
A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma. Oncotarget (2016) 0.75
Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Res (2016) 0.75
Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss. Hum Pathol (2016) 0.75
(18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep (2016) 0.75
Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. Elife (2016) 0.75
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget (2016) 0.75
Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med (2017) 0.75
Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife (2017) 0.75
Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. Curr Osteoporos Rep (2017) 0.75
*K-means and cluster models for cancer signatures. Biomol Detect Quantif (2017) 0.75
Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene (2017) 0.75
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (1992) 7.68
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J (1993) 2.91
The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol (1993) 2.84
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Criteria for inference of chromothripsis in cancer genomes. Cell (2013) 2.51
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet (2013) 2.44
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep (2014) 2.27
Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell (2009) 2.21
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol (2010) 1.88
The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet (2014) 1.74
Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell (2013) 1.72
Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol (2011) 1.70
Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity. Mol Cell Biol (2011) 1.68
Pathogenesis of follicular lymphoma. J Clin Invest (2012) 1.66
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol (2005) 1.66
Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet (2000) 1.38
Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene (1997) 1.26
Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer (1997) 1.14
Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer (2002) 1.13
A multiplex real-time pcr assay for the detection of gene fusions observed in solid tumors. Lab Invest (2001) 1.09
Cohesin in development and disease. Development (2013) 1.06
Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest (2001) 1.02
Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet (1988) 1.02
The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors. Genes Chromosomes Cancer (2011) 1.02
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene (2011) 1.02
Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer (2001) 0.97
Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet (2013) 0.92
CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet Cytogenet (2001) 0.91
Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer (2007) 0.91
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood (2014) 0.91
DNA methylation and gene expression profiling of ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation. Sarcoma (2012) 0.83
Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol (2016) 0.83
RNA sequencing validation of the Complexity INdex in SARComas prognostic signature. Eur J Cancer (2016) 0.82
Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma. Pediatr Blood Cancer (2014) 0.81
Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. Pediatr Blood Cancer (2016) 0.75
Dedifferentiation in SDH-Deficient Gastrointestinal Stromal Tumor: A Report With Histologic, Immunophenotypic, and Molecular Characterization. Pediatr Dev Pathol (2019) 0.75
Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy. Cancer (2017) 0.75
Somatic Embryonic FGFR2 Mutations in Keratinocytic Epidermal Nevi. J Invest Dermatol (2016) 0.75
A mutational comparison of adult and adolescent and young adult (AYA) colon cancer. Cancer (2017) 0.75